Cost of therapy for cystic fibrosis in different age groups with consideration to the respiratory tract infection and complications

2021 ◽  
Vol 31 (2) ◽  
pp. 238-249
Author(s):  
E. G. Furman ◽  
V. V. Shadrina ◽  
T. Yu. Maksimycheva ◽  
V. D. Sherman ◽  
E. I. Kondratyeva
Keyword(s):  
Cystic Fibrosis ◽  
Respiratory Tract ◽  
Pharmacoeconomic Analysis ◽  
Age Groups ◽  
Eradication Therapy ◽  
Cost Savings ◽  
Hypothetical Patient ◽  
Severity Of The Disease ◽  
Cost Of Drugs ◽  
The Cost

Despite the low prevalence of cystic fibrosis (CF), the costs of treating this disease are significant for the healthcare system. The aim of this economic study was to assess the total cost of drugs per year for children with CF, depending on age and course of the disease.Methods. For this pharmacoeconomic analysis, groups of “hypothetical” patients were formed according to the characteristics of the course of CF, taking into account the required volume of basic CF therapy, antibiotic therapy, and complications.Results. The cost of basic treatment for CF patients of different ages and disease progression in the hypothetical patient models can vary greatly. The cost of CF therapy increases significantly with age and Pseudomonas aeruginosa respiratory infection, especially in the patients with chronic infection, concomitant polyposis sinusitis, and low nutritional status.Conclusion. Patients with CF require regular follow-up with control of the microflora of the respiratory tract and effective eradication therapy for P. aeruginosa and other pathogenic microorganisms. Reducing infection rates and the severity of the disease can lead to significant cost savings.

scholarly journals Clinical trials and drug cost savings for Italian health service

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Francesca D’Ambrosio ◽  
Gianfranco De Feo ◽  
Gerardo Botti ◽  
Arturo Capasso ◽  
Sandro Pignata ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Health Service ◽  
Market Price ◽  
Cost Savings ◽  
Antineoplastic Drugs ◽  
Experimental Drugs ◽  
Cost Of Drugs ◽  
The Cost ◽  
The Impact

Abstract Background The cost of anticancer drugs is constantly growing. The aim of this study was determine the impact in terms of cost reduction for anticancer drug in the Italian Health Service due to patient participation in clinical trials. Methods We evaluated the cost of drugs administered to patients treated in clinical trials at the National Cancer Institute of Naples in a four-week time period. Patients with a diagnosis of different cancers were considered, including adjuvant therapy and treatment for advanced disease, pharma sponsored and investigator initiated phase I, II and III clinical studies. We defined the expected standard treatment for each patient and we calculated the cost of the standard antineoplastic drugs that should be administered in clinical practice outside clinical trials. We used the market price of drugs to determine the cost savings value. Costs other than drugs were not included in the cost saving calculation. Results From 23.10.2017 to 17.11.2017, 126 patients were treated in 34 pharma sponsored and investigator initiated clinical trials, using experimental drugs provided free of charge by the sponsors, for an overall number of 152 cycles of therapy. If these patients were treated with conventional therapies in clinical practice the cost of antineoplastic drugs would account for 517,658 Euros, with an average of 5487 Euros saved per patients for a period of 4 weeks. Conclusions Clinical trials with investigational antineoplastic drugs provided free of charge by Sponsors render considerable cost savings, with a tangible benefit in clinical and administrative strategies to reduce drug expenditures.

scholarly journals The human respiratory tract microbial community structures in healthy and cystic fibrosis infants

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Marie-Madlen Pust ◽  
Lutz Wiehlmann ◽  
Colin Davenport ◽  
Isa Rudolf ◽  
Anna-Maria Dittrich ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Microbial Community ◽  
Respiratory Tract ◽  
Rare Species ◽  
Age Groups ◽  
Healthy Children ◽  
Metagenomic Sequencing ◽  
Human Respiratory Tract ◽  
Close Proximity ◽  
Microbial Community Structures

AbstractThe metagenome development of the human respiratory tract was investigated by shotgun metagenome metagenomic sequencing of cough swabs from healthy children and children with cystic fibrosis (CF) between 3 weeks and 6 years of age. A healthy microbial community signature was associated with increased absolute abundances in terms of bacterial–human cell ratios of core and rare species across all age groups, with a higher diversity of rare species and a tightly interconnected species co-occurrence network, in which individual members were found in close proximity to each other and negative correlations were absent. Even without typical CF pathogens, the CF infant co-occurrence network was found to be less stable and prone to fragmentation due to fewer connections between species, a higher number of bridging species and the presence of negative species correlations. Detection of low-abundant DNA of the CF hallmark pathogen Pseudomonas aeruginosa was neither disease- nor age-associated in our cohort. Healthy and CF children come into contact with P. aeruginosa on a regular basis and from early on.

Drug Treatment Costs: Projected Impact of Using the Integrated Management of Childhood Illnesses

2003 ◽  
Vol 33 (2) ◽  
pp. 86-88 ◽  
Author(s):  
R D Wammanda ◽  
C L Ejembi ◽  
T Iorliam
Keyword(s):  
Drug Treatment ◽  
Treatment Cost ◽  
Health Workers ◽  
Integrated Management ◽  
Cost Savings ◽  
Cost Effective ◽  
Inappropriate Drugs ◽  
Sick Children ◽  
Cost Of Drugs ◽  
The Cost

The strategy of integrated management of childhood illness (IMCI) aims at improving the skills of first level health workers and consequently, improving the survival chances of children. The guidelines have been shown to be cost-effective. We aimed to determine the potential impact of using IMCI guidelines on drug treatment cost. The cost of drugs prescribed for 129 sick children, by first level health workers, who were managed at three primary health facilities in Sabon Gari Local Government Area of Kaduna State, was calculated. The corresponding cost using the IMCI guidelines was also calculated. There were 74 males and 55 females (M:F=1.3:1). An average of 4.5 drugs per patient were prescribed by the health workers compared to 2.3 drugs per patient when using the IMCI guidelines. The total cost of drugs prescribed by the health workers was N15 279.39 with an average of N118.44 per child. The corresponding costs had the IMCI guidelines been used were N3 062.53 and N23.73, respectively. Treatment cost using the traditional method was 4.98 times more expensive than using methods advocated by the IMCI guidelines. The projected cost savings related to drugs when using IMCI guidelines were based on the assumption that inappropriate drugs would not be prescribed by health workers once they are introduced to and started using the IMCI guidelines.

scholarly journals Clinical trials and drug cost savings for Italian Health Service

2020 ◽  
Author(s):  
Francesca D’Ambrosio ◽  
Gianfranco De Feo ◽  
Gerardo Botti ◽  
Arturo Capasso ◽  
Sandro Pignata ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Health Service ◽  
Market Price ◽  
Cost Savings ◽  
Antineoplastic Drugs ◽  
Experimental Drugs ◽  
Cost Of Drugs ◽  
The Cost ◽  
The Impact

Abstract Background: The cost of anticancer drugs is constantly growing. The aim of this study was determine the impact in terms of cost reduction for anticancer drug in the Italian Health Service due to patient participation in clinical trials.Methods: We evaluated the cost of drugs administered to patients treated in clinical trials at the National Cancer Institute of Naples in a four-week time period. Patients with a diagnosis of different cancers were considered, including adjuvant therapy and treatment for advanced disease, pharma sponsored and investigator initiated phase I, II and III clinical studies. We defined the expected standard treatment for each patient and we calculated the cost of the standard antineoplastic drugs that should be administered in clinical practice outside clinical trials. We used the market price of drugs to determine the cost savings value. Costs other than drugs were not included in the cost saving calculation. Results: From 23.10.2017 to 17.11.2017, 126 patients were treated in 34 pharma sponsored and investigator initiated clinical trials, using experimental drugs provided free of charge by the sponsors, for an overall number of 152 cycles of therapy. If these patients were treated with conventional therapies in clinical practice the cost of antineoplastic drugs would account for 517,658 Euros, with an average of 5,487 Euros saved per patients for a period of four weeks.Conclusions: Clinical trials with investigational antineoplastic drugs provided free of charge by Sponsors render considerable cost savings, with a tangible benefit in clinical and administrative strategies to reduce drug expenditures.

scholarly journals Hypertonic saline in the treatment of patients with cystic fibrosis in Russian Federation

2021 ◽  
pp. 156-165
Author(s):  
E. I. Kondatyeva ◽  
V. D. Sherman ◽  
V. V. Shadrina
Keyword(s):  
Cystic Fibrosis ◽  
Hypertonic Saline ◽  
Russian Federation ◽  
Annual Cost ◽  
Pharmacoeconomic Analysis ◽  
Sodium Hyaluronate ◽  
Ease Of Use ◽  
Number Of Patients ◽  
The Russian Federation ◽  
The Cost

Introduction. Mucolytic therapy is basic in the treatment of patients with cystic fibrosis (CF). Currently, inhalation of hypertonic saline (HS) of NaCl is recommended for the treatment of CF patients.The aim of the study was to investigate the experience of the use of HS NaCl for inhalations CF patients in the Russian Federation.Material and methods. To estimate the use of HS NaCl, data of national registers for 2011–2019 were used. Pharmacoeconomic analysis of “HS 7% NaCl + 0.1% sodium hyaluronate”, presented in the Russian market, carried out according to the cost estimate for the course of therapy based on the cost from the site of the unified information system in the sphere of procurement.Results. From 2011 to 2019, an increase in the number of patients receiving the inhalation of a HS is observed. 2011 –8.7% of patients with CF, by 2019 – in 71.5% of CF patients. In 25 regions of the Russian Federation more than 80% of CF patients used HS NaCl. The cost analysis of Russian-made medicinal products for human use containing 7% HS and 0.1% sodium hyaluronate solution, and foreign-made products of similar composition showed that the annual cost of therapy with Russian-made products was 2.15 times lower than that with the foreign-made products. As for the medicinal product mannitol, the annual cost of therapy with a foreign-made product is 8.1 times higher than the cost of a Russian-made product.Conclusions. The clinical practice of treating patients with CF has accumulated positive use of HS in inhalations, the use of which has increased significantly since 2011. Medical products 3 and 7% HS with a 0.1% solution of sodium hyaluronate are prescribed from the moment of diagnosis and have advantages over the HS pharmacy production over portability and ease of use. The use of the “7% HS with a 0.1% solution of sodium hyaluronate” is mainly determined by the financial accessibility.

Exploration-Stage Implementation Variation

2014 ◽  
Vol 222 (1) ◽  
pp. 37-48 ◽  
Author(s):  
Stephanie Romney ◽  
Nathaniel Israel ◽  
Danijela Zlatevski
Keyword(s):  
Parent Training ◽  
Average Cost ◽  
Cost Savings ◽  
Training Group ◽  
Group Differences ◽  
Triple P ◽  
Community Based ◽  
Parent Training Program ◽  
A Site ◽  
The Cost

The present study examines the effect of agency-level implementation variation on the cost-effectiveness of an evidence-based parent training program (Positive Parenting Program: “Triple P”). Staff from six community-based agencies participated in a five-day training to prepare them to deliver a 12-week Triple P parent training group to caregivers. Prior to the training, administrators and staff from four of the agencies completed a site readiness process intended to prepare them for the implementation demands of successfully delivering the group, while the other two agencies did not complete the process. Following the delivery of each agency’s first Triple P group, the graduation rate and average cost per class graduate were calculated. The average cost-per-graduate was over seven times higher for the two agencies that had not completed the readiness process than for the four completing agencies ($7,811 vs. $1,052). The contrast in costs was due to high participant attrition in the Triple P groups delivered by the two agencies that did not complete the readiness process. The odds of Triple P participants graduating were 12.2 times greater for those in groups run by sites that had completed the readiness process. This differential attrition was not accounted for by between-group differences in participant characteristics at pretest. While the natural design of this study limits the ability to empirically test all alternative explanations, these findings indicate a striking cost savings for sites completing the readiness process and support the thoughtful application of readiness procedures in the early stages of an implementation initiative.

Haemophilia Registry of the Medical Committee of the Swiss Haemophilia Society

2009 ◽  
Vol 29 (S 01) ◽  
pp. S16-S18 ◽  
Author(s):  
B. Brand ◽  
N. von der Weid
Keyword(s):  
Quality Control ◽  
Infectious Diseases ◽  
Mutation Analysis ◽  
Clinical Data ◽  
Age Groups ◽  
Treatment Modalities ◽  
Global Survey ◽  
On Demand ◽  
Per Capita ◽  
Severity Of The Disease

SummaryThe Swiss Haemophilia Registry of the Medical Committee of the Swiss Haemophilia Society was established in 2000. Primarily it bears epidemiological and basic clinical data (incidence, type and severity of the disease, age groups, centres, mortality). Two thirds of the questions of the WFH Global Survey can be answered, especially those concerning use of concentrates (global, per capita) and treatment modalities (on-demand versus prophylactic regimens). Moreover, the registry is an important tool for quality control of the haemophilia treatment centres.There are no informations about infectious diseases like hepatitis or HIV, due to non-anonymisation of the data. We plan to incorporate the results of the mutation analysis in the future.

Respiratory tract microbiocenosis in children with cystic fibrosis in Kharkiv region

2016 ◽  
Vol 78 (6) ◽  
pp. 24-26
Author(s):  
V.A. Klymenko ◽  
◽  
Y.A. Yanovskaya ◽  
Y.V. Pasichnik ◽  
◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Respiratory Tract

REKAYASA NILAI HARGA PEMBUATAN TERHADAP EFEKTIFITAS PENGGUNAAN BAHAN PADA PEMBANGUNAN PERUMAHAN TIRTO PENATARAN ASRI TIPE 70/135 KECAMATAN NGLEGOK KABUPATEN BLITAR

2017 ◽  
Vol 7 (1) ◽  
pp. 43-52
Author(s):  
Mochamad Tamim Ma’ruf
Keyword(s):  
Engineering Application ◽  
Cost Savings ◽  
Comparison Method ◽  
Value Engineering ◽  
Design Work ◽  
Housing Projects ◽  
Initial Design ◽  
A Value ◽  
The Cost ◽  
Design Proposal

One-solving methods and techniques necessary to avoid inefficiencies and not economic costs as well as reduce the cost of housing construction is the method of Value Engineering. Value engineering is a method and cost control techniques to analyze a function to its value at the lowest cost alternative (most economical) without reducing the quality desired.At the writing of this study used a comparison method by comparing the initial design to the design proposal of the author. In the housing projects Upgrading Tirto Penataran Asri type 70, the application of Value Engineering conducted on the job a couple walls and roofs pair by replacing some work items with a more economical alternative but does not change the original function and high aesthetic level and still qualify safe. For that performed the step of determining a work item, the alternative stage, the analysis stage, and the stage of recommendations to get a Value Engineering application and cost savings against the wall a couple of work items and partner roof.The proposed design as compared to the initial design. Work items discussed was the work of a couple wall having analyzed obtained savings of Rp. 2,747,643.56 and the work of the roof pair obtained savings of Rp. 2,363,446.80. Thus the total overall savings gained is Rp 5,111,090.36 or savings of 0048%.

Cost-minimization analysis of drugs used in the treatment of Asthma and COPD diseases in India

2020 ◽  
Vol 15 ◽  
Author(s):  
Billu Payal ◽  
Anoop Kumar ◽  
Harsh Saxena
Keyword(s):  
Generic Drugs ◽  
Cost Minimization ◽  
Cost Savings ◽  
Chronic Obstructive ◽  
Pulmonary Medicine ◽  
Potential Cost ◽  
Maximum Cost ◽  
Cost Minimization Analysis ◽  
Cost Variation ◽  
The Cost

Background: Asthma and Chronic Obstructive Pulmonary Diseases (COPD) are well known respiratory diseases affecting millions of peoples in India. In the market, various branded generics, as well as generic drugs, are available for their treatment and how much cost will be saved by utilizing generic medicine is still unclear among physicians. Thus, the main aim of the current investigation was to perform cost-minimization analysis of generic versus branded generic (high and low expensive) drugs and branded generic (high expensive) versus branded generic (least expensive) used in the Department of Pulmonary Medicine of Era Medical University, Lucknow for the treatment of asthma and COPD. Methodology: The current index of medical stores (CIMS) was referred for the cost of branded drugs whereas the cost of generic drugs was taken from Jan Aushadi scheme of India 2016. The percentage of cost variation particularly to Asthma and COPD regimens on substituting available generic drugs was calculated using standard formula and costs were presented in Indian Rupees (as of 2019). Results: The maximum cost variation was found between the respules budesonide high expensive branded generic versus least expensive branded generic drugs and generic versus high expensive branded generic. In combination, the maximum cost variation was observed in the montelukast and levocetirizine combination. Conclusion: In conclusion, this study inferred that substituting generic antiasthmatics and COPD drugs can bring potential cost savings in patients.

Sign in / Sign up

Export Citation Format

Share Document